Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
|Slideshows|August 13, 2018
Top 10 Cancer Treatment Stats Health Execs Should Know
Author(s)Mark Rowh
If it's true that a picture is worth a thousand words, the same can be said for numbers. For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.
Advertisement
If it's true that a picture is worth a thousand words, the same can be said for numbers. For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.
Advertisement
Related to this article
γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
Upstream payment accuracy should reduce avoidable noise before it reaches those downstream functions.
The results come several months after the FDA approved Lisraya for dermatomyositis.
Psychedelic therapies are nearing FDA decisions, but people with HIV, many covered by Medicaid, have been left out of nearly all trials, commentary authors argue.
Christopher Stanley, M.D., MBA, says Henry Ford Health now projects its 2027 employee healthcare insurance premiums to increase half as much as what had been expected, partly because of Populance’s to bring about cost-effective care.
David Feldshon, M.D., a Yale gastroenterologist who still performs endoscopy two days a week at 75, discusses his approach to MASLD and life outside the clinic.
Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Calibrating biologic treatment of HS to the response patterns to biologics
2
Quick Q&A: Christopher Stanley, M.D., MBA, on population health and healthcare affordability
3
As psychedelic drugs near FDA decisions, people with HIV remain absent from trials, commentary says
4
After a 10-year gap, FDA approves new option for pretreated head and neck cancer
5